CA2295926A1 - Procedes de diagnostic et de traitement du cancer, et procedes d'identification de marqueurs pathogenes dans un echantillon de cellules normales - Google Patents
Procedes de diagnostic et de traitement du cancer, et procedes d'identification de marqueurs pathogenes dans un echantillon de cellules normales Download PDFInfo
- Publication number
- CA2295926A1 CA2295926A1 CA002295926A CA2295926A CA2295926A1 CA 2295926 A1 CA2295926 A1 CA 2295926A1 CA 002295926 A CA002295926 A CA 002295926A CA 2295926 A CA2295926 A CA 2295926A CA 2295926 A1 CA2295926 A1 CA 2295926A1
- Authority
- CA
- Canada
- Prior art keywords
- scp
- cells
- protein
- subject
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 86
- 206010028980 Neoplasm Diseases 0.000 title claims description 43
- 238000003745 diagnosis Methods 0.000 title description 3
- 230000001717 pathogenic effect Effects 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 43
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 33
- 102100036234 Synaptonemal complex protein 1 Human genes 0.000 claims abstract description 25
- PUPNJSIFIXXJCH-UHFFFAOYSA-N n-(4-hydroxyphenyl)-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide Chemical compound C1=CC(O)=CC=C1NC(=O)CN1S(=O)(=O)C2=CC=CC=C2C1=O PUPNJSIFIXXJCH-UHFFFAOYSA-N 0.000 claims abstract description 21
- 101710143177 Synaptonemal complex protein 1 Proteins 0.000 claims abstract description 16
- 239000000126 substance Substances 0.000 claims abstract description 13
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 10
- 230000001575 pathological effect Effects 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 105
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 52
- 230000014509 gene expression Effects 0.000 claims description 30
- 239000002299 complementary DNA Substances 0.000 claims description 26
- 230000002159 abnormal effect Effects 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 23
- 210000001550 testis Anatomy 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 150000007523 nucleic acids Chemical class 0.000 claims description 15
- 101150103019 SCP gene Proteins 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 12
- 239000013598 vector Substances 0.000 claims description 12
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 11
- 239000006166 lysate Substances 0.000 claims description 8
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 230000002062 proliferating effect Effects 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 206010018338 Glioma Diseases 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 230000005867 T cell response Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 3
- 108010063738 Interleukins Proteins 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 230000000692 anti-sense effect Effects 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000003018 immunoassay Methods 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 238000003752 polymerase chain reaction Methods 0.000 claims description 3
- 229930182490 saponin Natural products 0.000 claims description 3
- 150000007949 saponins Chemical group 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940121649 protein inhibitor Drugs 0.000 claims 2
- 239000012268 protein inhibitor Substances 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 230000001461 cytolytic effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 238000009877 rendering Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 3
- 230000010307 cell transformation Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 239000000523 sample Substances 0.000 description 21
- 238000013459 approach Methods 0.000 description 16
- 238000003556 assay Methods 0.000 description 12
- 101710134395 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 Proteins 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102100037686 Protein SSX2 Human genes 0.000 description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000021121 meiosis Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000726252 Mus musculus Cysteine-rich secretory protein 1 Proteins 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000008627 meiotic prophase Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 101000880774 Homo sapiens Protein SSX4 Proteins 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 238000002306 biochemical method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010968 computed tomography angiography Methods 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102100031673 Corneodesmosin Human genes 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 101000836297 Haemophilus aegyptius Type II restriction enzyme HaeIII Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000880771 Homo sapiens Protein SSX3 Proteins 0.000 description 1
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100037726 Protein SSX3 Human genes 0.000 description 1
- 102100037727 Protein SSX4 Human genes 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 101150002637 SSX1 gene Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 101500022167 Youcai mosaic virus Replicase small subunit Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 201000007698 cell type cancer Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000003783 haploid cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- -1 i.e. Proteins 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004217 synaptonemal complex Anatomy 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/892,702 | 1997-07-15 | ||
| US08/892,702 US5888751A (en) | 1997-07-15 | 1997-07-15 | Method for diagnosis and treating cancers, and methods for identifying pathogenic markers in a sample of normal cells |
| PCT/US1998/013209 WO1999004040A1 (fr) | 1997-07-15 | 1998-06-25 | Procedes de diagnostic et de traitement du cancer, et procedes d'identification de marqueurs pathogenes dans un echantillon de cellules normales |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2295926A1 true CA2295926A1 (fr) | 1999-01-28 |
Family
ID=25400375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002295926A Abandoned CA2295926A1 (fr) | 1997-07-15 | 1998-06-25 | Procedes de diagnostic et de traitement du cancer, et procedes d'identification de marqueurs pathogenes dans un echantillon de cellules normales |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US5888751A (fr) |
| EP (1) | EP0998582A4 (fr) |
| JP (1) | JP2001510056A (fr) |
| KR (1) | KR100384402B1 (fr) |
| CN (1) | CN1159453C (fr) |
| AU (1) | AU729715B2 (fr) |
| CA (1) | CA2295926A1 (fr) |
| HK (1) | HK1027597A1 (fr) |
| NZ (1) | NZ502217A (fr) |
| WO (1) | WO1999004040A1 (fr) |
| ZA (1) | ZA986277B (fr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998050911A2 (fr) * | 1997-05-02 | 1998-11-12 | Lee Howard Hong Dough | Dispositif de traitement de l'information haute performance multifonction |
| US6291658B1 (en) * | 1997-05-05 | 2001-09-18 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding SSX family members and thereof |
| US6287756B1 (en) * | 1997-05-05 | 2001-09-11 | Ludwig Institute For Cancer Research | Methods for determining presence of cancer in a sample by determining expression of an SSX gene |
| US6140050A (en) * | 1998-06-26 | 2000-10-31 | Ludwig Institute For Cancer Research | Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith |
| US6214983B1 (en) * | 1998-10-22 | 2001-04-10 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode SCP proteins |
| US6261778B1 (en) * | 1998-10-22 | 2001-07-17 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules which encode SCP proteins, and uses thereof |
| WO2000050595A2 (fr) * | 1999-02-25 | 2000-08-31 | Ivan Gout | Molecules d'acide nucleique associees aux melanomes et aux tumeurs de la thyroide |
| US6448073B1 (en) | 2000-01-28 | 2002-09-10 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| AU2002350071A1 (en) * | 2001-06-22 | 2003-01-08 | Ludwig Institute For Cancer Research | Methods for detection of disease-associated antibodies in urine |
| US6864324B2 (en) * | 2002-04-19 | 2005-03-08 | Chem First Electronic Materials L.P. | Anhydrous, liquid phase process for preparing hydroxyl containing polymers of enhanced purity |
| KR100475449B1 (ko) * | 2002-06-10 | 2005-03-10 | (주)프로테옴텍 | 유방암 진단용 마커 |
| US7178491B2 (en) * | 2003-06-05 | 2007-02-20 | Caterpillar Inc | Control system and method for engine valve actuator |
| AU2004249254B2 (en) * | 2003-06-17 | 2010-07-08 | Mannkind Corporation | Combinations of tumor-associated antigens for the treatment of various types of cancers |
| WO2006071989A2 (fr) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methodes de declenchement, d'accentuation et de maintien de reponses immunitaires contre des epitopes restreints du cmh de classe i a des fins prophylactiques ou therapeutiques |
| BRPI0611794A2 (pt) | 2005-06-17 | 2010-09-28 | Mannkind Corp | métodos e composições para induzir respostas imunes multivalentes contra epìtopos dominantes e subdominantes, expressos em células de cáncer e estroma tumoral |
| US20070031876A1 (en) * | 2005-08-08 | 2007-02-08 | Hsueh-Kung Lin | Methods of providing gene expression profiles for metastatic cancer phenotypes utilizing differentially expressed transcripts associated with circulating tumor cells |
| KR20090003153A (ko) * | 2006-04-03 | 2009-01-09 | 몰레큘러 임프린츠 인코퍼레이티드 | 다수의 필드와 정렬 마크를 갖는 기판을 동시에 패턴화하는방법 |
| WO2012166722A1 (fr) * | 2011-06-03 | 2012-12-06 | The General Hospital Corporation | Traitement du cancer colorectal, pancréatique et pulmonaire |
| US8478545B2 (en) * | 2011-06-03 | 2013-07-02 | Agilent Technologies, Inc. | Identification of aberrant microarray features |
| WO2015085105A1 (fr) * | 2013-12-04 | 2015-06-11 | University Of Alaska Fairbanks | Procédés et compositions pour enrichir des séquences non-hôtes dans des échantillons hôtes |
| JP2018535692A (ja) | 2015-09-21 | 2018-12-06 | エラスムス ユニバーシティ メディカル センターＥｒａｓｍｕｓ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ | 抗ｃｄ４７抗体及び使用方法 |
| DE102017108254B4 (de) | 2016-04-19 | 2019-10-02 | GM Global Technology Operations LLC | Rundumsichtkamerasystem zur Objekterkennung und -verfolgung und Verfahren zum Ausstatten eines Fahrzeugs mit einem Rundumsichtkamerasystem |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468481A (en) * | 1988-06-23 | 1995-11-21 | Amergen, Inc. | MHC class II-peptide conjugates useful in ameliorating autoimmunity |
| US5733550A (en) * | 1990-05-10 | 1998-03-31 | Dana-Farber Cancer Institute, Inc. | Method for enhancing the association of exogenous peptides with class I MHC molecules on the surface of antigen presenting cells with β-microglobulin |
| US5824315A (en) * | 1993-10-25 | 1998-10-20 | Anergen, Inc. | Binding affinity of antigenic peptides for MHC molecules |
-
1997
- 1997-07-15 US US08/892,702 patent/US5888751A/en not_active Expired - Lifetime
-
1998
- 1998-06-25 EP EP98932861A patent/EP0998582A4/fr not_active Withdrawn
- 1998-06-25 WO PCT/US1998/013209 patent/WO1999004040A1/fr not_active Application Discontinuation
- 1998-06-25 AU AU82649/98A patent/AU729715B2/en not_active Ceased
- 1998-06-25 JP JP2000503245A patent/JP2001510056A/ja active Pending
- 1998-06-25 KR KR10-2000-7000490A patent/KR100384402B1/ko not_active IP Right Cessation
- 1998-06-25 CA CA002295926A patent/CA2295926A1/fr not_active Abandoned
- 1998-06-25 US US09/104,324 patent/US6232460B1/en not_active Expired - Lifetime
- 1998-06-25 CN CNB98807141XA patent/CN1159453C/zh not_active Expired - Fee Related
- 1998-06-25 NZ NZ502217A patent/NZ502217A/en unknown
- 1998-07-15 ZA ZA986277A patent/ZA986277B/xx unknown
- 1998-09-29 US US09/162,713 patent/US6239256B1/en not_active Expired - Lifetime
-
2000
- 2000-10-27 HK HK00106860A patent/HK1027597A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US5888751A (en) | 1999-03-30 |
| CN1159453C (zh) | 2004-07-28 |
| ZA986277B (en) | 1999-04-15 |
| AU729715B2 (en) | 2001-02-08 |
| EP0998582A1 (fr) | 2000-05-10 |
| KR100384402B1 (ko) | 2003-06-27 |
| US6239256B1 (en) | 2001-05-29 |
| HK1027597A1 (en) | 2001-01-19 |
| JP2001510056A (ja) | 2001-07-31 |
| AU8264998A (en) | 1999-02-10 |
| CN1263560A (zh) | 2000-08-16 |
| KR20010021926A (ko) | 2001-03-15 |
| EP0998582A4 (fr) | 2004-10-13 |
| WO1999004040A1 (fr) | 1999-01-28 |
| NZ502217A (en) | 2001-06-29 |
| US6232460B1 (en) | 2001-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5888751A (en) | Method for diagnosis and treating cancers, and methods for identifying pathogenic markers in a sample of normal cells | |
| EP0711173B1 (fr) | Peptides isoles formant des complexes avec la molecule mhc du clone hla-c 10 et utilisation de ceux-ci | |
| JP3799483B2 (ja) | ガン関連抗原をコードする単離核酸分子、その抗原、およびそれらの利用方法 | |
| US6287756B1 (en) | Methods for determining presence of cancer in a sample by determining expression of an SSX gene | |
| EP0822993B1 (fr) | Procedes de diagnostic et therapie genique faisant appel a des reactifs derives du gene suppresseur de metastases humain kai1 | |
| US6548064B1 (en) | Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules | |
| CN100378121C (zh) | 分离的结合mhcⅰ类和mhcⅱ类分子的同ny－eso－1的氨基酸序列相关的肽及其应用 | |
| US6800730B1 (en) | Isolated peptides which bind to MHC class II molecules, and uses thereof | |
| US6982316B1 (en) | Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer | |
| EP1005532B1 (fr) | Molecules d'acides nucleiques isolees codant des membres de la famille ssx et utilisations de ces molecules | |
| US7270819B2 (en) | Isolated nucleic acid molecules encoding isolated peptides which correspond to contiguous amino acids of an SSX molecule or NY-ESO-1 and uses thereof | |
| US6261778B1 (en) | Isolated nucleic acid molecules which encode SCP proteins, and uses thereof | |
| US6306389B1 (en) | Isolated SCP proteins and uses thereof | |
| US20060115817A1 (en) | Span-xb gene and protein for the diagnosis and treatment of cancer | |
| CA2165435C (fr) | Nouveaux precurseurs d'antigenes pour le rejet des tumeurs et molecules d'acides nucleiques codant pour ces precurseurs | |
| JP2003520604A (ja) | 癌関連抗原をコードする単離された核酸分子、癌関連抗原そのものおよびそれらの使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |